Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates

Targeting PCSK9 and ANGPTL3 with statin regresses atherosclerosis

Posted on 29 January 2020 | Posted in News

In a mouse model of hyperlipidaemia, the combination of the PCSK9 inhibitor alirocumab, a monoclonal antibody to ANGPTL3 (angiopoietin-like 3 protein) evinacumab, and atorvastatin not only reduced LDL cholesterol by 73% but also regressed atherosclerosis.

Read the article:  Pouwer MG, et al. Alirocumab, evinacumab, and atorvastatin triple therapy regresses plaque lesions and improves lesion composition in mice. J Lipid Res 2019; doi: 10.1194/jlr.RA119000419. [Epub ahead of print] PUBMED

Read the accompanying editorial: Hurt-Camejo E.  Combination ANGPTL3, PCSK9 and statin therapy drives remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model. J Lipid Res 2020;doi: 10.1194/jlr.C120000650. [Epub ahead of print]


Related content

Evinacumab, ANGPTL3 inhibitor, awarded breakthrough status by FDA

EAS Congress Innsbruck: Mixed results with novel agents in homozygous FH